Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Related Research units
Abstract
Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML).
Bibliographical data
| Original language | English |
|---|---|
| Article number | 28 |
| ISSN | 0732-183X |
| Publication status | Published - 2012 |
| pubmed | 22949154 |
|---|
